167 results
Page 2 of 9
8-K
EX-99.3
umc2z0ci 33xi5u3r57e
11 Dec 20
Lexicon Announces Offering of Common Stock
5:28pm
424B5
bxb dg4iszm0
11 Dec 20
Prospectus supplement for primary offering
8:02am
424B5
ba2q2d8x0 uvhtg
30 Oct 20
Prospectus supplement for primary offering
5:11pm
8-K
y7vovrxal8atm9iq3
8 Sep 20
Termination of a Material Definitive Agreement
5:02pm
8-K
EX-99.1
036dm
30 Jul 20
Lexicon Pharmaceuticals Enters into Agreement
7:18am
8-K
EX-99.1
ufbck18gocbyu2h1bubb
30 Jul 20
Lexicon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides a Business Update
7:04am
8-K
azzacst
29 May 20
Termination of a Material Definitive Agreement
4:33pm
8-K
EX-99.1
lr2af11zrdq2mbku4315
27 Apr 20
Lexicon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides a Business Update
7:04am
DEFA14A
d8rb2sshyvxivlr7th5f
7 Apr 20
Additional proxy soliciting materials
4:57pm
8-K
EX-99.1
3furtduq
12 Mar 20
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-year 2019 Financial Results and Provides a Business Update
7:04am
8-K
EX-99.1
6fzspbfctlxezka7
7 Nov 19
Lexicon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides a Business Update
7:06am
8-K
EX-99.1
p202 djdq
10 Sep 19
Lexicon Pharmaceuticals Announces Termination of Alliance and Settlement with Sanofi
4:03pm
8-K
EX-99.1
tnbqbcflt 558q
31 Jul 19
Lexicon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides a Business Update
7:11am
8-K
EX-99.1
ds63tixl6vmg1p
29 Jul 19
Lexicon Pharmaceuticals Provides Preliminary Update for Zynquistatm (Sotagliflozin) Type 2 Diabetes Phase 3 Program
12:00am
8-K
EX-99.1
rc8a422bn2aai4ha71
1 May 19
Lexicon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides a Business Update
7:17am